Verona Pharma
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 79
- Market Cap
- -
- Website
- http://www.veronapharma.com
- Introduction
Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 180
- Registration Number
- NCT06559150
- Locations
- 🇺🇸
Southeastern Research Center, Winston-Salem, North Carolina, United States
🇺🇸ASHA Clinical Research, Hammond, Indiana, United States
🇺🇸TPMG Clinical Research, Williamsburg, Virginia, United States
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects with COPD
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 46
- Registration Number
- NCT06545500
- Locations
- 🇺🇸
Clinical Research of West Florida Inc - Clearwater, Clearwater, Florida, United States
🇺🇸Clinical Research of West Florida Inc - Tampa, Tampa, Florida, United States
🇺🇸Midwest Chest Consultants PC, Saint Charles, Missouri, United States
Effect of Ensifentrine Treatment on CAT Score
- First Posted Date
- 2024-06-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 20
- Registration Number
- NCT06460493
- Locations
- 🇺🇸
Midwest Chest Consultants, St. Charles, Missouri, United States
Effect of Ensifentrine on Sputum Markers of Inflammation in COPD
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 50
- Registration Number
- NCT05270525
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2020-09-09
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 790
- Registration Number
- NCT04542057
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Clinical Trials of Florida. LLC, Miami, Florida, United States
🇺🇸Research Institute of South Florida, Miami, Florida, United States
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 763
- Registration Number
- NCT04535986
- Locations
- 🇺🇸
AMR Tempe, Tempe, Arizona, United States
🇺🇸Phoenix Medical Group, Peoria, Arizona, United States
🇺🇸TPMG Clinical Research Williamsburg, Williamsburg, Virginia, United States
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 40
- Registration Number
- NCT04091360
- Locations
- 🇬🇧
Medicines Evaluation Unit Limited, Wythenshawe, United Kingdom
🇬🇧Respiratory Clinical Trials Ltd, London, United Kingdom
Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler
- First Posted Date
- 2019-07-22
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 37
- Registration Number
- NCT04027439
- Locations
- 🇺🇸
VitaLink Research -- Union, Union, South Carolina, United States
Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD
- Conditions
- Interventions
- Drug: Ensifentrine (formerly RPL554) 0.75 mg twice daily plus placebo, in addition to tiotropiumDrug: Ensifentrine (formerly RPL554) 0.375 mg twice daily plus placebo, in addition to tiotropiumDrug: Ensifentrine (formerly RPL554) placebo twice daily, in addition to tiotropiumDrug: Ensifentrine (formerly RPL554) 1.5 mg twice daily plus placebo, in addition to tiotropiumDrug: Ensifentrine (formerly RPL554) 3.0 mg twice daily plus placebo, in addition to tiotropium
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2020-11-20
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 416
- Registration Number
- NCT03937479
- Locations
- 🇺🇸
Vitalink Research-Spartanburg, Spartanburg, South Carolina, United States
🇺🇸FMC Science, LLC, Lampasas, Texas, United States
🇺🇸DCOL Center for Clinical Research, Longview, Texas, United States
Bronchodilator Effect of RPL554 Administered in Addition to Tiotropium/Olodaterol in Patients With COPD
- Conditions
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- Verona Pharma plc
- Target Recruit Count
- 79
- Registration Number
- NCT03673670
- Locations
- 🇺🇸
Allied Biomedical Research Holdings, d/b/a Vitalink Research, Greenville, South Carolina, United States
🇬🇧Respiratory Clinical Trials LTD,, London, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom